Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer
Jhanelle E. Gray, Jeffrey C. Thompson, Erica L. Carpenter, et al.
The Oncologist (2021) Vol. 26, Iss. 10, pp. e1812-e1821
Open Access | Times Cited: 22

Showing 22 citing articles:

Next Generation Sequencing Technology in Lung Cancer Diagnosis
Călin Căinap, Ovidiu Bălăcescu, Simona Căinap, et al.
Biology (2021) Vol. 10, Iss. 9, pp. 864-864
Open Access | Times Cited: 72
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors
Jeffrey C. Thompson, Dylan Scholes, Erica L. Carpenter, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 12, pp. 1893-1902
Open Access | Times Cited: 26
Liquid Biopsies in Lung Cancer
Marcel Kemper, Carolin Krekeler, Kerstin Menck, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1430-1430
Open Access | Times Cited: 25
Multiplex Digital Methylation‐Specific PCR for Noninvasive Screening of Lung Cancer
Yang Zhao, Christine M. O’Keefe, Kuangwen Hsieh, et al.
Advanced Science (2023) Vol. 10, Iss. 16
Open Access | Times Cited: 22
Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review
Bartłomiej Tomasik, Marcin Skrzypski, Michał Bieńkowski, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 3, pp. 594-614
Open Access | Times Cited: 18
Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer
Melissa Y. Tjota, Jeremy P. Segal, Peng Wang
The Journal of Applied Laboratory Medicine (2024) Vol. 9, Iss. 1, pp. 76-91
Closed Access | Times Cited: 7
Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
Jia Li Low, Sun Min Lim, Jii Bum Lee, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 15
The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population
Sibo Liu, Nicholas Graves, Aaron C. Tan
Lung Cancer (2024) Vol. 191, pp. 107794-107794
Open Access | Times Cited: 5
Universal lung epithelium DNA methylation markers for detection of lung damage in liquid biopsies
Judith Magenheim, Ariel Rokach, Ayelet Peretz, et al.
European Respiratory Journal (2022) Vol. 60, Iss. 5, pp. 2103056-2103056
Open Access | Times Cited: 16
Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer
Karolina Buszka, Aliki Ntzifa, Barbara Owecka, et al.
Cells (2022) Vol. 11, Iss. 18, pp. 2871-2871
Open Access | Times Cited: 13
The Importance of Biomarker Testing in the Treatment of Advanced Non-Small Cell Lung Cancer: A Podcast
Fred R. Hirsch, Chul Kim
Oncology and Therapy (2024) Vol. 12, Iss. 2, pp. 223-231
Open Access | Times Cited: 2
Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation
Clement Chung, Godsfavour Umoru
Journal of Oncology Pharmacy Practice (2024)
Closed Access | Times Cited: 1
The Emerging Applications of Raman Spectroscopy in Clinical Oncology: A Narrative Review Focused on Circulating Tumor DNA Detection and Therapeutic Drug Monitoring
S. Narayanan, Yuling Wang, Howard Gurney
Onco (2024) Vol. 4, Iss. 4, pp. 335-348
Open Access | Times Cited: 1
The Role of Liquid Biopsy in the Diagnostic Testing Algorithm for Advanced Lung Cancer
Aaron C. Tan
Onco (2022) Vol. 2, Iss. 3, pp. 181-185
Open Access | Times Cited: 5
Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients
Michael Fleischhacker, Erkan Arslan, Dana Reinicke, et al.
(2023)
Open Access | Times Cited: 2
THE ROLE OF NEXT-GENERATION SEQUENCING IN LUNG CANCER DIAGNOSIS
Julia Moskalenko, О. І. Vynnychenko, Oksana Sulaieva, et al.
Eastern Ukrainian Medical Journal (2023) Vol. 11, Iss. 3, pp. 214-223
Open Access | Times Cited: 2
Assessing Outcomes in NSCLC: Radiomic analysis, kinetic analysis and circulating tumor DNA
Ashray Maniar, Alexander Z. Wei, Laurent Dercle, et al.
Seminars in Oncology (2022) Vol. 49, Iss. 3-4, pp. 298-305
Closed Access | Times Cited: 3
Clinical utility of plasma cell-free DNA (cfDNA) in diffuse gliomas for the detection of IDH1 R132H mutation
Swati Singh, Supriya Bhardwaj, Iman Dandapath, et al.
Pathology - Research and Practice (2024) Vol. 263, pp. 155571-155571
Closed Access
Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors
Arafat Tfayli, Hady Ghanem, Fadi Nasr, et al.
Future Oncology (2024), pp. 1-11
Closed Access
Could DNA Fragments Be the Key to Early Detection of Lung Cancer?
Jeffrey C. Thompson, Anil Vachani
American Journal of Respiratory and Critical Care Medicine (2023) Vol. 207, Iss. 9, pp. 1120-1122
Open Access | Times Cited: 1
Precision medicine-based cancer care
Stephanie Santos, Eddy S. Yang
Elsevier eBooks (2023), pp. 272-283
Closed Access
Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients
Michael Fleischhacker, Erkan Arslan, Dana Reinicke, et al.
Diagnostics (2023) Vol. 13, Iss. 13, pp. 2131-2131
Open Access
Page 1

Scroll to top